Quote Request
Whole-Cancer Cell Vaccine Development for Pancreatic Cancer
Welcome to Alfa Cytology, your premier destination for pioneering cancer treatment solutions. We specialize in preclinical research for whole-cancer cell vaccine development, providing the foundational work needed to advance therapeutic strategies for pancreatic cancer. Our expertise and cutting-edge technology ensure that your research is supported by rigorous scientific methodologies.
Overview of Whole-Cancer Cell Vaccine for Pancreatic Cancer
Whole-cancer cell vaccines work by presenting the immune system with a diverse set of tumor-associated antigens (TAAs). These vaccines are created using cancer cells that have been inactivated so they cannot cause disease. The immune system is then trained to recognize and attack cancer cells by exposing it to these inactivated cells. Here's how the mechanism works:
- Antigen Presentation: The inactivated whole-cancer cells retain a complete set of TAAs present in the live tumor cells. When introduced into the body, these antigens are processed and presented by antigen-presenting cells (APCs), such as dendritic cells.
- Immune Activation: APCs present these antigens to T cells in the lymph nodes, stimulating an immune response. Both cytotoxic T lymphocytes (CTLs) and helper T cells are activated.
- Immune Memory Formation: The immune system develops a memory of these antigens, allowing it to recognize and respond more quickly and effectively if the cancer cells reappear.
- Tumor Targeting: Activated T cells and other immune cells seek out and destroy any remaining cancer cells in the body that express the same antigens.
Fig. 1 Mechanism of whole tumor cell-based vaccines (Pérez-Baños, et al., 2022)
Our Services
Whole-cancer cell vaccine development is an innovative approach that utilizes entire cancer cells to stimulate the patient's immune system. Unlike vaccines that target a single antigen, whole-cancer cell vaccines present a wide array of tumor-associated antigens. This broad antigenic presentation can elicit a more robust and comprehensive immune response, making it a promising strategy for treating pancreatic cancer. At Alfa Cytology, we focus on the preclinical stages of this vaccine development, providing crucial insights and data that pave the way for clinical trials and therapeutic applications.
Cancer Cell Vaccine Design and Preparation
Our vaccine development platform consists of dozens of scientists dedicated to translating fundamental knowledge about the PC immune system and its regulation in PC into the design of more effective vaccines and vaccine regimens. We can design and prepare cancer cell vaccines with different vectors as well as vector targets including autologous tumor cells and allogeneic tumor cells, and cell lines.
Cancer Cell Vaccine Modification
After killing tumor cells by freeze-thawing and irradiation, because these unmodified tumor cells do not generate a robust immune response, subsequent work has focused on enhancing the immunogenicity of tumor cell vaccines by genetic modification. We offer many different strategies to genetically modify tumor cells to make them more immunogenic, including the introduction of cytokine molecules, xeno- or immunogenic antigens, viral tumor lysis products, and/or co-stimulatory molecules.
Cancer Cell Vaccine Evaluation
The anti-tumor efficacy and safety of the cancer cell vaccine will be tested in preclinical models prior to translation to human clinical trials. We offer a range of PDAC models for preclinical vaccine evaluation, including PC cell model, syngeneic xenograft as well as transgenic and humanized mice. We are now offering the following whole-cancer cell vaccine evaluation services, but are not limited to:
- Viability study of cancer cell vaccines
- Anti-tumor efficacy test of cancer cell vaccines
- Toxicity evaluation of cancer cell vaccines
Why Choose Us?
Tailored Solutions
Advanced Technology
Professional Expertise
Collaborative Approach
As a leading company in preclinical research for cancer immunotherapy, Alfa Cytology is committed to advancing the science of pancreatic cancer treatment. Our specialized whole-cancer cell vaccine development services provide critical insights and data, propelling the journey towards effective therapeutic solutions. Contact us today to learn more about how our preclinical expertise can support your research endeavors.
References
- Pérez-Baños, A., Gleisner, M.A., Flores, I. et al. Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. Br J Cancer 129, 572–585 (2023).
- Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022 Oct 13;9(1):53.
